| Patent Number |
Title Of Patent |
Date Issued |
| RE37650 |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
April 9, 2002 |
| This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation. |
| RE36256 |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyro |
July 20, 1999 |
| This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such |
| 6852712 |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck t |
February 8, 2005 |
| This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56.sup.lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subjec |
| 6846815 |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck t |
January 25, 2005 |
| This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or sub |
| 6821962 |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck |
November 23, 2004 |
| This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56.sup.lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subjec |
| 6696434 |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck t |
February 24, 2004 |
| This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56.sup.lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subjec |
| 6645969 |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
November 11, 2003 |
| This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl qu |
| 6559313 |
Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties |
May 6, 2003 |
| This invention is directed to intermediates of the formula ##STR1##wherein Z is 4-trifluoromethylpyridin-2-yl or 5-trifluoromethylpyridin-2-yl which are useful in the preparation of compounds useful as antihypertensive, anti-ischemic, cardioprotective, and antilipolytic agents. |
| 6528526 |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck t |
March 4, 2003 |
| This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56.sup.lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subjec |
| 6524347 |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck t |
February 25, 2003 |
| This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or sub |
| 6482834 |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck t |
November 19, 2002 |
| This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56.sup.lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subjec |
| 6376472 |
Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
April 23, 2002 |
| A compound of the formula ##STR1##wherein K is N; Q is CH.sub.2 or O; R.sub.6 is hydrogen, alkyl, allyl, 2-methylallyl, 2-butenyl, or cycloalkyl ##STR2##where the nitrogen of the ring of X is substituted by Y; E is O or S; Y is hydrogen, alkyl, aralkyl, substituted aralkyl, aryl, sub |
| 6323227 |
Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
November 27, 2001 |
| This invention relates to compounds of formula ##STR1##which inhibit Factor Xa, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibi |
| 6245760 |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck t |
June 12, 2001 |
| This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56.sup.lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subjec |
| 6180632 |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck t |
January 30, 2001 |
| This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56.sup.lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subjec |
| 6159978 |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56.sup. |
December 12, 2000 |
| This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or sub |
| 6140504 |
Substituted intermediate compounds for the preparation of n-[(aminoiminomethyl or aminomethyl)ph |
October 31, 2000 |
| Compounds of the formula: ##STR1## |
| 6080767 |
Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
June 27, 2000 |
| The compounds according to the invention are substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides of formula I herein which exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients |
| 6057320 |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyros |
May 2, 2000 |
| This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such |
| 6034093 |
Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
March 7, 2000 |
| The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The |
| 5958918 |
Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminominomethyl)p |
September 28, 1999 |
| The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The pres |
| 5795889 |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyro |
August 18, 1998 |
| This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such |
| 5736554 |
Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
April 7, 1998 |
| Compounds of the Formula ##STR1## wherein: K is N or N.fwdarw.O; Q is CH.sub.2 or O; T is ##STR2## or R.sub.3 O--CH.sub.2 ; X is a straight or branched chain alkylene, cycloalkylene or cycloalkenylene group, each of which is optionally substituted by at least one CH.sub.3, CH |
| 5731315 |
Substituted sulfonic acid n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclamide compounds |
March 24, 1998 |
| The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The |
| 5721237 |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of |
February 24, 1998 |
| This invention relates to a method for the selective treatment of cell growth and differentiation characterized by activity of the human epidermal growth factor receptor type 2 (HER2). More specifically, this invention relates to the use of substituted or unsubstituted mono- or bi-cy |
| 5714493 |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
February 3, 1998 |
| This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation. |
| 5710158 |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
January 20, 1998 |
| This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl qu |
| 5677329 |
Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyros |
October 14, 1997 |
| Methods of inhibiting cell proliferation in a patient suffering from such disorder comprising the use of a styryl-substituted heteroaryl compound wherein the heteroaryl group is a monocyclic ring with 1 or 2 heteroatoms, or a bicyclic ring with 1 to about 4 heteroatoms, said compound opt |
| 5656655 |
Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase |
August 12, 1997 |
| A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a pharmaceutically effective amount of a pharmaceutical composition containing, in admixture with a pharmaceutically acceptable carrier, a compound, or |
| 5656643 |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyros |
August 12, 1997 |
| This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such |
| 5652366 |
DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof |
July 29, 1997 |
| This invention relates to di[(1 R)-(-)-camphosulfonic acid) salt of [1S-[1.alpha.,2.beta.,3.beta.,4.alpha.,(S*)]]-4-[7-[[2-(3-chloro-2-thienyl )-1-ethylethyl]amino]3 H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentanecarboxamide , and a process for preparing the compound, c |
| 5646153 |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyro |
July 8, 1997 |
| This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such |
| 5612353 |
Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl) |
March 18, 1997 |
| The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is |
| 5597837 |
Method and composition for treating psoriasis with styryl-substituted pyridyl compounds |
January 28, 1997 |
| Methods of inhibiting cell proliferation in a patient suffering from such disorder comprising the use of a styryl-substituted heteroaryl compound wherein the heteroaryl group is a monocyclic ring with 1 or 2 heteroatoms, or a bicyclic ring with 1 to about 4 heteroatoms, said compound opt |
| 5561134 |
Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
October 1, 1996 |
| Compounds of the Formula ##STR1## wherein: K is N or N.fwdarw.O; Q is CH.sub.2 or O; T is ##STR2## or R.sub.3 O--CH.sub.2 ; X is a straight or branched chain alkylene, cycloalkylene or cycloalkenylene group, each of which is optionally substituted by at least one CH.sub.3, CH |
| 5556990 |
Polyarylcarbamoylaza- and -carbamoylalkanedioic acids |
September 17, 1996 |
| This invention relates to a class of novel dicarboxy amide derivatives of lipophilic amines which exhibit squalene synthase inhibition properties. More specifically the compounds are bis-aryl and/or heteroaryl alkyl or cycloalkylamino dicarboxy amides. Compounds of this invention reduce |
| 5480883 |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyro |
January 2, 1996 |
| This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such |
| 5476851 |
Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase |
December 19, 1995 |
| This invention relates to pyrazolo[3,4-g]quinoxaline compounds exhibiting protein tyrosine kinase inhibition activity of the formula: ##STR1## where: ------ may be a double bond;R, R.sub.2, R.sub.3 and R.sub.4 are as described in claim 1;a pharmaceutically acceptable salt thereof.More sp |
| 5418245 |
Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyros |
May 23, 1995 |
| Methods of inhibiting cell proliferation in a patient suffering from such disorder comprising the use of a styryl-substituted heteroaryl compound wherein the heteroaryl group is a monocyclic ring with 1 or 2 heteroatoms, or a bicyclic ring with 1 to about 4 heteroatoms, said compound opt |
| 5409930 |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyro |
April 25, 1995 |
| This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such |
| 5364862 |
Compounds having antihypertensive and anti-ischemic properties |
November 15, 1994 |
| This invention relates to adenosine derivatives and analogs which possess adenosine agonist activity and are useful as anti-hypertensive and anti-ischemic agents, to pharmaceutical compositions including such compounds, and to their use in treating hypertension and myocardial ischemi |
| 5302606 |
Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
April 12, 1994 |
| Methods of inhibiting cell proliferation in a patient suffering from such disorder comprising the use of a styryl-substituted heteroaryl compound wherein the heteroaryl group is a monocyclic ring with 1 or 2 heteroatoms, or a bicyclic ring with 1 to about 4 heteroatoms, said compound opt |
| 5217982 |
Compounds having antihypertensive properties |
June 8, 1993 |
| This invention relates to compounds which are derivatives of cyclopentane which are useful as antihypertensive agents, to pharmaceutical compositions including such compounds, and to their use in treating hypertension. |
| 5015638 |
Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same |
May 14, 1991 |
| This invention relates to substituted pyridooxazinone and naphtheridone pyridones which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including the same |
| 5002944 |
Compounds having cardiotonic activity |
March 26, 1991 |
| Compounds useful for increasing cardiotonic contractility in humans or other animals and pharmaceutical compositions including these compounds are disclosed. The compounds have the general structure: ##STR1## where A is ##STR2## R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.9, an |
| 4906629 |
Pyridazinone and pyrazolone compounds, cardiotonic compositions including same, and their uses |
March 6, 1990 |
| This invention relates to substituted pyridooxazinone and naphtheridone pyridazinone and pyrazolone compounds which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical |
| 4866074 |
Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same |
September 12, 1989 |
| This invention relates to substituted pyridooxazinone and naphtheridone pyridones which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including the same |
| 4859672 |
Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone |
August 22, 1989 |
| Compounds useful for increasing cardiotonic contractility in humans or other animals and pharmaceutical compositions including these compounds are disclosed. The compounds have the general structure ##STR1## wherein: A is ##STR2## and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.su |
| 4829066 |
Pyridooxazinone-pyridazinone and pyrazolone compounds, cardiotonic compositions including the sa |
May 9, 1989 |
| This invention relates to substituted pyridooxazinone pyridazinone and pyrazolone compounds, which are useful as cardiotonic agents for the treatment of congestive heart failure. This invention also relates to methods for increasing cardiac contractility using said compounds, and pha |
| 4822794 |
Pyridooxazinone-pyridone compounds, cardiotonic compositions including the same, and their uses |
April 18, 1989 |
| This invention relates to substituted pyridooxazinone pyridones which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including the same. |
